Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis

WENG Lizhu

doi:10.3969/j.issn.1006-0111.2014.01.017

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To compare the clinical effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis(TB). Methods From Jan 2011 to Dec 2012, 108 patients who were proved to be multi-drug resistant to tuberculosis in Yuhuan County People's Hospital of Zhejiang Province were included in the study. The patients were divided into moxifloxacin treatment group or levofloxacin treatment group by computer-generated random number and randomly allocated method. The treatment regimens were as follows:in moxifloxacin treatment group, the patients were given moxifloxacin, pasiniazid, pyrazinamide, protionamide, rifapentine, sodium aminosalicylate, and amikacin for 3 months, followed by 6 months treatment of moxifloxacin, pyrazinamide, protionamide, pasiniazid and rifapentine, then moxifloxacin, rifapentine, pyrazinamide, andpasiniazid for 9 months. In levofloxacin treatment group, moxifloxacin was replaced by levofloxacin, and other combinations were same as moxifloxacin group. The treatment time was 18 months in 2 groups. Results At the end of the study, 41 of 53 patients finished the treatment in moxifloxacin-group and 44 of 55 patients finished the treatment in levofloxacin-group. Mortalities were 9.4%(5/53)in moxifloxacin-group and 9.1%(5/55) in levofloxacin-group, respectively. The sputum negative rate was 87.8%(36/41) and 84.1%(37/44) in each group, respectively. The effective rate of chest X ray was 92.7%(38/41) in moxifloxacin group and 93.2%(41/44) in levofloxacin group, and the cavity closure rate were 39%(16/41)and 43.2%(19/44). The rate of serious adverse drug reactions was 13.2%(7/53) and 10.9%(6/55), respectively. There was no significant difference between 2 groups. Conclusion Moxifloxacin combined with other drugs to treat multi-drug-resistant TB had no significant advantages compared to levofloxacin combined with the same drugs.

Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis

Department of Infectious Diseases, Yuhuan County People's Hospital of Zhejiang Province, Yuhuan 317600, China

Received Date: 2013-04-23

Rev Recd Date: 2013-09-06

Key words:

Abstract: Objective To compare the clinical effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis(TB). Methods From Jan 2011 to Dec 2012, 108 patients who were proved to be multi-drug resistant to tuberculosis in Yuhuan County People's Hospital of Zhejiang Province were included in the study. The patients were divided into moxifloxacin treatment group or levofloxacin treatment group by computer-generated random number and randomly allocated method. The treatment regimens were as follows:in moxifloxacin treatment group, the patients were given moxifloxacin, pasiniazid, pyrazinamide, protionamide, rifapentine, sodium aminosalicylate, and amikacin for 3 months, followed by 6 months treatment of moxifloxacin, pyrazinamide, protionamide, pasiniazid and rifapentine, then moxifloxacin, rifapentine, pyrazinamide, andpasiniazid for 9 months. In levofloxacin treatment group, moxifloxacin was replaced by levofloxacin, and other combinations were same as moxifloxacin group. The treatment time was 18 months in 2 groups. Results At the end of the study, 41 of 53 patients finished the treatment in moxifloxacin-group and 44 of 55 patients finished the treatment in levofloxacin-group. Mortalities were 9.4%(5/53)in moxifloxacin-group and 9.1%(5/55) in levofloxacin-group, respectively. The sputum negative rate was 87.8%(36/41) and 84.1%(37/44) in each group, respectively. The effective rate of chest X ray was 92.7%(38/41) in moxifloxacin group and 93.2%(41/44) in levofloxacin group, and the cavity closure rate were 39%(16/41)and 43.2%(19/44). The rate of serious adverse drug reactions was 13.2%(7/53) and 10.9%(6/55), respectively. There was no significant difference between 2 groups. Conclusion Moxifloxacin combined with other drugs to treat multi-drug-resistant TB had no significant advantages compared to levofloxacin combined with the same drugs.

HTML

Reference (10)

[1]	朱莉贞,傅瑜,初乃惠,等.利福类联合多种药物长疗程方案治疗耐多药肺结核[J].中华结核和呼吸杂志,2006,29(8):320-323.
[2]	Centers for Disease Control and Prevention (CDC).Emergence of mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide,2000-2004[J].MMWR Morb Mortal Wkly ReP,2006,55(11):301-305.
[3]	Centers for Disease Control and Prevention (CDC).Plan to combat extensively drug resistant tuberculosis:recommendations of the Federal Tuberculosis Task Force[J].MMWR Recomm ReP,2009,58(RR-3):1-43.
[4]	Musser JM. Antimicrobial agent resistantce in mycrobacteria:molecular genetic insights[J]. Clin Microbiol Rev,1995,8(2):495-514.
[5]	何国钧.多重耐药性结核病及其治疗[J].中国防痛杂志,1997,19(增刊):30-32.
[6]	曾正国.现代实用结核病学[M].北京:科学技术文献出版社,2003:228-235.
[7]	Fattorini L,Tan D,lona E,et al. Activity of moxifloxacin alone and in combination with other antimicrobial agents multidrug-resistant mycrobacterium tuberculosis infection in BALB/c mice[J]. Antimicrob Agents Chemother,2003,47(1):360-362.
[8]	Nuermberger EL,Yoshimatsu T. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis[J]. Am J Respir Crit Care Med,2004,170(10):1131-1134.
[9]	Johnson JL,Hadad DJ.Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis[J]. Int J Tuberc Lung Dis,2006,10(6):605-612.
[10]	梁丽丽,刘欣.联合应用莫西沙星或左氧氟沙星治疗耐多药肺结核疗效研究[J].中国全科医学,2011,13:1451-1453.

Message Board

Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis

doi: 10.3969/j.issn.1006-0111.2014.01.017

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views